MiRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells

Oncogene

Volumn 32, Issue 39, 2013, Pages 4712-4720

  Kliese, N ^a   Gobrecht, P ^a   Pachow, D ^a   Andrae, N ^a   Wilisch Neumann, A ^a   Kirches, E ^a   Riek Burchardt, M ^b   Angenstein, F ^b   Reifenberger, G ^c   Riemenschneider, M ^d   Meese, E ^e   Panayotova Dimitrova, D ^f   Gutmann, D H ^g   Mawrin, C ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b LEIBNIZ INSTITUTE FOR NEUROBIOLOGY   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

collagen type 5; invasion; meningioma; miRNA

Indexed keywords

COLLAGEN TYPE 5; COLLAGEN TYPE 5 ALPHA; MICRORNA 145; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MENINGIOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; CELL ADHESION; CELL DIFFERENTIATION; CELL DIVISION; CELL MOVEMENT; COLLAGEN TYPE V; DOWN-REGULATION; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; MICRORNAS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; RNA, NEOPLASM; TUMOR STEM CELL ASSAY;

MUS MUSCULUS;

EID: 84884906415     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.468     Document Type: Article

References (31)

1. CBTRUS. Central brain tumor registry of the United States 2012.
2. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010; 99: 379391.
3. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999; 85: 20462056.
4. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 2002; 161: 665672.
5. Stuart JE, Lusis EA, Scheck AC, Coons SW, Lal A, Perry A et al. Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol 2011; 70: 112.
6. Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R et al. Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol 2010; 12: 844854.
7. Mawrin C, Wolke C, Haase D, Kruger S, Firsching R, Keilhoff G et al. Reduced Activity of CD13/aminopeptidase N (APN) in aggressive meningiomas is associated with increased levels of SPARC. Brain Pathol 2009; 20: 200210.
8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857866.
9. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 37533756.
10. Liang S, He L, Zhao X, Miao Y, Gu Y, Guo C et al. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One 2011; 6: e18409.
11. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R et al. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282: 3258232590.
12. La Rocca G, Shi B, Badin M, De Angelis T, Sepp-Lorenzino L, Baserga R et al. Growth inhibition by microRNAs that target the insulin receptor substrate-1. Cell Cycle 2009; 8: 22552259.
13. Gao P, Xing A-Y, Zhou G-Y, Zhang T-G, Zhang J-P, Gao C et al. The molecular mechanism of microRNA-145 to suppress invasionmetastasis cascade in gastric cancer. Oncogene 2013; 32: 491501.
14. Gotte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29: 65696580.
15. Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, James MF et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 2009; 29: 59235940.
16. Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010; 103: 256264.
17. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 2011; 32: 772778.
18. Koo S, Martin GS, Schulz KJ, Ronck M, Toussaint LG. Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. BMC Cancer 2012; 12: 143.
19. Black PM. Meningiomas. Neurosurgery 1993; 32: 643657.
20. Kilic T, Bayri Y, Ozduman K, Acar M, Diren S, Kurtkaya O et al. Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape. Neurosurgery 2002; 51: 183192.
21. Nordqvist AC, Smurawa H, Mathiesen T. Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. J Neurosurg 2001; 95: 839844.
22. De Paepe A, Nuytinck L, Hausser I, Anton-Lamprecht I, Naeyaert JM. Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II. Am J Hum Genet 1997; 60: 547554.
23. Symoens S, Malfait F, Renard M, Andre J, Hausser I, Loeys B et al. COL5A1 signal peptide mutations interfere with protein secretion and cause classic Ehlers-Danlos syndrome. Hum Mutat 2009; 30: E395E403.
24. Wenstrup RJ, Florer JB, Davidson JM, Phillips CL, Pfeiffer BJ, Menezes DW et al. Murine model of the Ehlers-Danlos syndrome. col5a1 haploinsufficiency disrupts collagen fibril assembly at multiple stages. J Biol Chem 2006; 281: 1288812895.
25. Nitta H, Yamashima T, Yamashita J, Kubota T. An ultrastructural and immunohistochemical study of extracellular matrix in meningiomas. Histol Histopathol 1990; 5: 267274.
26. Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Bornemann A et al. Patterns of SPARC expression and basement membrane intactness at the tumourbrain border of invasive meningiomas. Neuropathol Appl Neurobiol 2006; 32: 525531.
27. Puttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH et al. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest 2005; 85: 11631171.
28. Lee WH. Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery 1990; 27: 389395, discussion 396.
29. Ragel BT, Couldwell WT, Gillespie DL, Wendland MM, Whang K, Jensen RL et al. A comparison of the cell lines used in meningioma research. Surg Neurol 2008; 70: 295307.
30. Tanaka K, Sato C, Maeda Y, Koike M, Matsutani M, Yamada K et al. Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer 1989; 64: 22432249.
31. Kirches E, Andrae N, Hoefer A, Kehler B, Zarse K, Leverkus M et al. Dual role of the mitochondrial protein frataxin in astrocytic tumors. Lab Invest 1766; 91: 17661776.